Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Russia has proved resilient to western sanctions, says Oleg Deripaska
    • Covid antiviral drug linked to ‘transmissible’ mutations, research finds
    • Chinese TV presenter linked to missing foreign minister had surrogate child in US
    • How TSMC’s chip plant is shaking up Japan
    • Global trade falls at fastest pace since pandemic
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • ‘Get off the train’: Citi’s Jane Fraser sends tough message on big overhaul
      • Meta pays £149mn to break London office lease
      • Glencore traded thousands of tonnes of Russian copper through Turkey
      • Santander ditched EY as financial crime consultant over alleged failings
      • Big Four accountancy firms shed UK staff after pandemic hiring boom
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • The debt-fuelled bet on US Treasuries that’s scaring regulators
      • Live news: Hunter Biden sues Rudy Giuliani for alleged computer fraud
      • Glencore traded thousands of tonnes of Russian copper through Turkey
      • Sterling heads for worst month since Liz Truss’s ‘mini’-Budget
      • US Treasuries sell off as investors fret over long period of high rates
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • What the world should expect from a second Trump term
      • US Republicans could finally win the argument on immigration
      • The problem with power parents
      • How the US is crushing Europe’s domestic exchanges
      • Net zero was never going to be an easy win for workers
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Paternity leave in finance: ‘The more men do it, the less of a big deal it becomes’
      • The activist sued by Elon Musk: ‘We have to show we will not be cowed’
      • Success is more complicated than one exceptional individual
      • What Burberry taught me about the marketed mind
      • Can I start a business when I have MS?
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • This Is New York review — exhibition captures the city’s unique joy, terror and exhilaration
      • The generation divide in British chess 
      • Raffles London and the new era of super-luxe hospitality
      • The best museum gift shops in the world
      • Game, set, matched – when David Shrigley met Andy Murray
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Moderna

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Tuesday, 26 September, 2023
      Covid-19 vaccines
      EU in talks with Moderna over new vaccine supply deal

      Brussels launches talks for mRNA jabs to augment existing contract with BioNTech/Pfizer

      A pharmacist administers a Covid jab made by Moderna
    • Wednesday, 13 September, 2023
      Lex
      Moderna: searching for a second act after Covid Premium content

      Despite progress on a flu jab, the biotech group will be lossmaking for the next three years

      Filling a syringe with vaccine
    • Wednesday, 13 September, 2023
      Moderna’s mRNA flu vaccine shows promising results

      Trial finds latest version elicited better immune response than existing jabs

      A healthcare worker prepares a dose of the Moderna Covid-19 vaccine
    • Monday, 11 September, 2023
      Covid-19 vaccines
      FDA approves new Covid-19 boosters from Pfizer and Moderna

      Drug regulator’s decision is the first step towards a new round of jabs as cases rise in the US

      A nurse fills a syringe with Covid-19 vaccine
    • Thursday, 17 August, 2023
      Covid-19 vaccines
      Jonathan Van-Tam takes role at vaccine maker Moderna

      Prominent figure in UK pandemic response becomes medical consultant at pharma group

      Sir Jonathan Van-Tam
    • Wednesday, 5 July, 2023
      US biotech Moderna strikes deal to develop mRNA drugs in China

      Medicines produced by pharma group will be for domestic use only

      Someone is preparing a syringe with Moderna’s vaccine against Covid-19
    • Monday, 1 May, 2023
      Noubar Afeyan
      Moderna co-founder calls on US politicians and judges to stop questioning science

      Noubar Afeyan says court rulings on abortion pills and access to healthcare undermine efforts to combat diseases

      Noubar Afeyan
    • Friday, 28 April, 2023
      Special ReportThe Americas’ Fastest Growing Companies
      Moderna tries to show it’s not a ‘one trick pony’

      Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects

      A health worker prepares a dose of the Moderna COVID-19 vaccine
    • Tuesday, 11 April, 2023
      FT live news
      IMF lowers growth outlook, Sweden’s top pension fund fires chief on banking losses
    • Tuesday, 14 March, 2023
      Covid-19 vaccines
      Pfizer’s revised EU Covid vaccine contract meets resistance

      Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots

      Lab worker with vials
    • Monday, 2 January, 2023
      LexDrugs research
      Moderna/BioNTech: cancer vaccines will show mRNA not a one-trick pony Premium content

      Success in battle against Covid does not ensure success against tumours, but should narrow the odds

      A nurse prepares a dose of Moderna’s Covid vaccine
    • Tuesday, 13 December, 2022
      Drugs research
      Moderna’s mRNA cancer vaccine shows promise in early trial

      Study suggests combination with Merck immunotherapy drug reduces risk of death in high-risk patients

      Moderna’s logo is reflected in a drop on a syringe needle
    • Tuesday, 8 November, 2022
      Covid-19 vaccines
      Patent wars: Moderna’s battle for the spoils of Covid vaccines

      Ending of pharma group’s IP truce spells fight for future of mRNA technology

      A dose of the Moderna Covid-19 vaccine is prepared in Los Angeles
    • Thursday, 3 November, 2022
      Moderna cuts Covid vaccine sales forecast

      Jab maker ties weaker revenue outlook to delivery delays and manufacturing issues

      Moderna vaccine vials
    • Sunday, 16 October, 2022
      Covid-19 vaccines
      Vaccine makers face revenue slump as demand falls for Covid jabs

      Pharmaceutical companies hunt for new revenue streams as coronavirus becomes endemic

      A woman receives a dose of the BioNTech/Pfizer vaccine
    • Thursday, 13 October, 2022
      InterviewCovid-19 vaccines
      Beijing’s failure to import mRNA Covid jabs ‘mind-boggling’, says BeiGene executive

      Chinese biotech’s research chief calls decision ‘unfortunate’ as zero-Covid policy strangles economy

      A researcher at a BeiGene laboratory
    • Saturday, 1 October, 2022
      Moderna refused China request to reveal vaccine technology

      Pharma company still ‘eager’ to collaborate with Beijing, despite collapse of initial talks

      Montage of a syringe being inserted into a Moderna Covid-19 vial, China’s flag and DNA strands
    • Wednesday, 28 September, 2022
      Behind the Money podcast18 min listen
      Who will pay for the next Covid vaccines?

      Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic

    • Wednesday, 31 August, 2022
      Covid-19 vaccines
      US approves Omicron vaccines from Moderna and BioNTech/Pfizer

      FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections

      A medical worker prepares to administer a BioNTech/Pfizer Covid vaccine booster
    • Friday, 26 August, 2022
      Covid-19 vaccines
      Moderna accuses BioNTech/Pfizer of copying mRNA technology

      US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic

      Syringes with needles displayed in front of a Moderna logo
    • Monday, 15 August, 2022
      Covid-19 vaccines
      UK becomes first country to approve Omicron-specific Covid booster

      Moderna’s two-strain shot will target both the original strain and BA.1 in step with European regulators

      People wearing face coverings wait at a bus stop displaying a government advertisement promoting the NHS Covid-19 vaccine booster programme in London in December 2021
    • Sunday, 10 July, 2022
      FT SeriesLeading in a crisis
      Moderna’s Noubar Afeyan on the race to create a Covid vaccine

      The chair of the $60bn US biopharma group explains how his approach to combining science with entrepreneurship led to the company’s creation

      Noubar Afeyan, chair of biopharma group Moderna
    • Wednesday, 22 June, 2022
      Moderna calls for approval of two-strain Covid vaccine booster

      US biotech group says shot targeting both first strain and Omicron could help avert ‘large rise’ in cases

      The Moderna Covid-19 vaccine is loaded into a syringe
    • Wednesday, 22 June, 2022
      Covid-19 vaccines
      UK signs £1bn deal with Moderna for new vaccine centre

      Government seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech

      Moderna Covid-19 vaccines
    • Wednesday, 15 June, 2022
      Covid-19 vaccines
      FDA advisory panel backs Covid-19 vaccines for children under 5

      US prepares to roll out jabs to last age group without access once regulatory approval is received

      A child is administered a coronavirus vaccine
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

    Tools

    PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Visual and data journalism
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today’s Newspaper (FT Digital Edition)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In